3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Sarcoma
2
Neoplasms
2
Neuroblastoma
1
Neoplastic Syndromes, Hereditary
1
Neoplasm Metastasis
1
Hereditary Breast and Ovarian Cancer Syndrome
1
Colorectal Neoplasms, Hereditary Nonpolyposis
1
Colorectal Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
90
Blood Specimen Collection
41
Cyclophosphamide
37
Bevacizumab
36
Nivolumab
35
Standard of Care
32
Carboplatin
31
Surveys and Questionnaires
29
Paclitaxel
27
atezolizumab
25
Exercise
25
Pemetrexed
24
Gemcitabine
23
Cisplatin
23
Fluorouracil
22
Radiotherapy
20
Leucovorin
20
Dexamethasone
20
Docetaxel
19
Oxaliplatin
18
Rituximab
16
Irinotecan
16
Cetuximab
16
dostarlimab
15
Drug Therapy
15
Doxorubicin
15
Ipilimumab
14
Biopsy
14
130-nm albumin-bound paclitaxel
14
fludarabine
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms
×
High-Throughput Nucleotide Sequencing
×
1 year
×
Clear all
NCT02780128
2026-03-10
NEPENTHE
Children's Hospital of Philadelphia
Phase 1
Terminated
66 enrolled
NCT04261972
2026-01-14
CHARM1
University Health Network, Toronto
Active not recruiting
1,416 enrolled